In eight patients with uncomplicated non insulin dependent diabetes mellitus, serum insulin levels, serum C-peptide levels and blood glucose levels were measured before and after oral administration of glibenclamide 0.1 mg/kg body weight and a test meal, or after a test meal alone. The rise in serum insulin levels persisted longer after glibenclamide. The initial rise in serum insulin was of the same magnitude in both situations, as was the rise in serum C-peptide levels during the entire 5 h study. It is concluded that glibenclamide is able to maintain a more protonged increase in serum insulin levels by inhibiting the degradation of insulin in the vascular endothelial cells of the liver. The inhibition contributes to the blood glucose lowering effect of glibenclamide.

C-peptide, diabetes, glibenclamide, Insulin, insulin catabolism
dx.doi.org/10.1007/BF00265847, hdl.handle.net/1765/62537
European Journal of Clinical Pharmacology
Department of Internal Medicine

Mulder, H.W, Schopman, W, Sr., & van der Lely, A-J. (1991). Extrapancreatic insulin effect of glibenclamide. European Journal of Clinical Pharmacology, 40(4), 379–381. doi:10.1007/BF00265847